Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tianqi Pingchan Granule + Amantadine for L-DOPA-Induced Dyskinesia
NCT04173832Unknown
- Sponsor
- Xinhua Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- TCM (Traditional Chinese Medicine), HM (Herbal Medicine)
- Countries
- 1
01
Overview
Randomised, double-blind trial in levodopa-induced dyskinesia (LID) comparing Tianqi Pingchan Granule + Amantadine with Placebo + Amantadine (2 arms). Primary endpoint: Unified Dyskinesia Rating Scale at 12 weeks. Status: unknown.
02
Drugs
Tianqi Pingchan Granule
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT04173832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173832.